Human antibodies to PD-L1
The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
1. A method of inhibiting a tumor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to human programmed death ligand 1 (PD-L1) wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained in a heavy chain variable region (HCVR) comprising an amino acid sequence of SEQ ID NO: 82; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 90.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
(a) a HCDR1 domain having an amino acid sequence of SEQ ID NO: 84;
(b) a HCDR2 domain having an amino acid sequence of SEQ ID NO: 86;
(c) a HCDR3 domain having an amino acid sequence of SEQ ID NO: 88;
(d) a LCDR1 domain having an amino acid sequence of SEQ ID NO: 92;
(e) a LCDR2 domain having an amino acid sequence of SEQ ID NO: 94; and
(f) a LCDR3 domain having an amino acid sequence of SEQ ID NO: 96.
3. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 82/90.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof has one or more of the following properties:
(a) binds monomeric PD-L1 with a binding dissociation equilibrium constant (K D ) of less than about 310 pM as measured in a surface plasmon resonance assay at 37° C.;
(b) binds monomeric human PD-L1 with a K D less than about 180 pM in a surface plasmon resonance assay at 25° C.;
(c) binds dimeric human PD-L1 with a K D of less than about 15 pM as measured in a surface plasmon resonance assay at 37° C.; and
(d) binds dimeric human PD-L1 with a K D less than about 8 pM in a surface plasmon resonance assay at 25° C.
5. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof blocks binding of PD-L1 to programmed death 1 (PD-1) receptor.
6. The method of claim 1 , wherein the subject has primary or recurrent cancer.
7. The method of claim 1 , wherein the tumor is selected from the group consisting of brain cancer, renal cell carcinoma, ovarian cancer, gastric cancer, bladder cancer, breast cancer, prostate cancer, colon cancer, ovarian cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, myeloma, and melanoma.
8. The method of claim 1 , wherein the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, is administered to the subject in combination with a second therapeutic agent.
9. The method of claim 8 , wherein the second therapeutic agent is selected from the group consisting of radiation therapy, a chemotherapeutic agent, a cytotoxic agent, surgery, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin 2 (Ang-2) inhibitor, a cancer vaccine, an anti-PD-1 antibody, a transforming growth factor beta (TGFbeta) inhibitor, an epithelial growth factor receptor (EGFR) inhibitor, an antibody to a T-cell co-inhibitor, an antibody to a tumor specific antigen, a CD20 inhibitor, a corticosteroid, and a dietary supplement.
10. The method of claim 9 , wherein the pharmaceutical composition is administered in combination with a VEGF antagonist.
11. The method of claim 10 , wherein the VEGF antagonist is selected from the group consisting of an anti-VEGF antibody, a small molecule kinase inhibitor of VEGF receptor, and a VEGF-inhibiting fusion protein.
12. The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.
13. The method of claim 1 , wherein the antibody or antigen-binding fragment is administered at a dose of about 0.1 mg/kg of body weight to about 100 mg/kg of body weight of the subject.
14. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a HCVR of SEQ ID NO: 82 and a LCVR of SEQ ID NO: 90.
15. The method of claim 14 , wherein the antibody or antigen-binding fragment thereof comprises a HCDR1 of SEQ ID NO: 84, a HCDR2 of SEQ ID NO: 86, a HCDR3 of SEQ ID NO: 88, a LCDR1 of SEQ ID NO: 92, a LCDR2 of SEQ ID NO: 94, and a LCDR3 of SEQ ID NO: 96.